Vericel Corp, founded in 1989 in Ann Arbor, Michigan, is an American biopharmaceutical company headquartered in Cambridge, Massachusetts. The company specializes in developing personalized stem cell products for tissue repair and regeneration. Vericel's core products include MACI for cartilage repair, Epicel for severe burn care, and Carticel for cartilage defects. Additionally, Vericel holds exclusive North American commercial rights to NexoBrid, a biological orphan product for eschar removal in severe thermal burns.
Vericel has made significant strides in the biotechnology industry, becoming a component of both the Russell 2000 and S&P 600 indices. Under the leadership of CEO Nick Colangelo, COO Daniel Orlando, and CFO Gerard Michel, Vericel has expanded its market presence and impact. The company's innovative therapies have garnered positive patient testimonials and have established Vericel as a leader in advanced cell therapy products for sports medicine and burn care.
